PDCD10 and hepatocellular carcinoma: We also found that LB-100, a PP2A inhibitor with anticancer effects in many human malignancies [35], and with the enhancement effect of therapeutics for doxorubicin and cisplatin in HCC [36], significantly inhibited PP2Ac activity and HCC tumour growth and metastasis caused by PDCD10 overexpression, which provided a new way to treat HCC.